Strand Life Sciences has acquired a 68% stake in Venaxis. Under the deal, Strand’s shareholders, along with employees and directors who hold options in Strand, will own directly and beneficially approximately 68% of Venaxis, with the rest in the hands of Venaxis shareholders.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
